Gordon Reeves is a Cardiology physician affiliated with University of North Carolina at Chapel Hill. OpenAlex indexes 83 publications with 3,605 citations (h-index 25); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Medical Center Blvd
Winston Salem, NC 271573578
Telephone
336-716-6674Provider last certified this registry record 14 Aug 2023.
Clinical trials
- Frailty: Prevalence and Response to Left Ventricular Assist Device Therapy in Older Heart Failure Patients
Sponsor: Thomas Jefferson University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
21 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novo Nordisk IncProgram year20251 payment
- ABIOMEDProgram year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
57.7%Beta blocker16.8%Metoprolol Succinate66%Carvedilol19%Bisoprolol Fumarate15%Part D<11 patientsAngiotensin receptor-neprilysin inhibitor (ARNI)14.3%Entresto100%Part D≥31 patients+ 5 more classes in this area
Metabolism & gastrointestinal
26.4%SGLT2 inhibitor22.3%Jardiance84%Farxiga16%Part D<11 patientsProton pump inhibitor2.5%Pantoprazole Sodium100%Part D<11 patients+ 1 more class in this area
Blood & clotting
9.1%Factor Xa inhibitor5.1%Eliquis100%Part D<11 patientsP2Y12 inhibitor2.2%Clopidogrel100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Assessing and managing frailty in advanced heart failure: An International Society for Heart and Lung Transplantation consensus statement
The Journal of Heart and Lung Transplantation
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Lisa Carey, MD
University of North Carolina at Chapel Hill
Diana Perkins, MD
University of North Carolina at Chapel Hill
Norman Sharpless, MD
University of North Carolina at Chapel Hill
Douglas Drossman, MD
University of North Carolina at Chapel Hill
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Harlan Krumholz, MD
Yale School of Medicine
Scott Solomon, MD
Brigham and Women's Hospital
Eric Topol, MD
Scripps Research Institute (Scripps Research)
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”